Skip to content
Alivexis, Inc.
Unveiling the Future of Medicine
Menu
Home
Science
Pipeline
About Us
News
Public Notice
Contact Us
日本語
News
News
Alivexis Announces Receipt of Intention to Exercise Option Right from Astellas Pharma Inc. for Collaboration on Novel Drug Target
- 02 September, 2025
Notice of Selection for the Ministry of Economy, Trade and Industry’s Domestic Generative AI Development Strengthening Project “GENIAC”
- 15 July, 2025
Alivexis to Present at the 2025 BIO International Convention
- 27 May, 2025
Alivexis To Present at GTC 2025 Japan AI Day
- 11 March, 2025
Alivexis Raises $0.7M USD Series D in Second Close
- 03 March, 2025
PairMap: Revolutionizing Drug Discovery with Precise Energy Calculations
- 12 February, 2025
Alivexis Raises $5.1M USD Series D in First Close
- 07 January, 2025
Alivexis announces publication of a research article on its ground-breaking ModBind™ simulation technology
- 20 December, 2024
Alivexis to present ModBind™ at MACNICA booth at the AI EXPO Tokyo
- 28 October, 2024
Cathepsin C Inhibitor Proved Effective in the Treatment of Vasculitis～Expectations for a Novel Therapeutic Agent for ANCA-Associated Vasculitis～
- 23 August, 2024
Next
Press & Media Contact
Email address protected by JavaScript.
Please enable JavaScript to contact me.
Latest Release
Alivexis Announces Receipt of Intention to Exercise Option Right from Astellas Pharma Inc. for Collaboration on Novel Drug Target
Notice of Selection for the Ministry of Economy, Trade and Industry’s Domestic Generative AI Development Strengthening Project “GENIAC”
Alivexis to Present at the 2025 BIO International Convention
Alivexis To Present at GTC 2025 Japan AI Day
Alivexis Raises $0.7M USD Series D in Second Close
